NCT01012310View on ClinicalTrials.gov

Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

April 30, 2010

Conditions
Healthy Volunteers
Interventions
DRUG

PF-04531083 or Placebo

Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.

DRUG

PF-04531083 or Placebo

Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.

DRUG

PF-04531083 or Placebo

Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.

DRUG

PF-04531083 or Placebo

A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.

Trial Locations (1)

1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01012310 - Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects | Biotech Hunter | Biotech Hunter